Wakix (Pitolisant HCl) Patent Expiration, LOE Window & CMS Spending

Wakix (Pitolisant HCl) by Harmony Management: FDA Orange Book core substance LOE 2030-03-07 (last listed 2033-02-13), 3 AB generics, $250.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarmony Management
FDA Application & PathwayN211150 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-03-07
Last Listed Patent or Exclusivity Date2033-02-13
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$250.5M
2024 Medicare Part D Spend$132.5M
2024 Medicaid Spend$118.1M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.5% 2-yr change)